Massimiliano Camilli Highlights the Need for Standardized Cardio-Oncology Education – Oncodaily

AI News Q&A (Free Content)

Q1: What are the current challenges in cardio-oncology education as highlighted by Massimiliano Camilli?

A1: Massimiliano Camilli has emphasized significant gaps in cardio-oncology education during medical school, residency, and structured institutional programs. A survey conducted by the ESC Council of Cardio-Oncology revealed these educational gaps, prompting a need for standardized training and certification across all levels of medical education to better prevent and manage cardiovascular complications in cancer patients.

Q2: How is the European Society of Cardiology addressing the educational gaps in cardio-oncology?

A2: The European Society of Cardiology (ESC) has developed a Core Curriculum for Cardio-Oncology alongside new ESC Guidelines to standardize training. These initiatives aim to fill the educational gaps identified in the survey and provide a foundation for the ESC Cardio-Oncology certification, which is intended to improve the prevention, recognition, and treatment of cardiovascular complications in cancer patients.

Q3: What are the benefits of standardized cardio-oncology education according to recent reports?

A3: Standardized cardio-oncology education ensures that healthcare professionals are equipped with the necessary skills and knowledge to manage cardiotoxicities in cancer patients effectively. It facilitates early recognition, consistent surveillance, and timely referral, which are crucial for preserving cancer treatment intensity while minimizing cardiovascular morbidity.

Q4: What role does exercise play in cardio-oncology according to recent scholarly articles?

A4: Exercise is identified as an underutilized prevention strategy for cardiotoxicities in cardio-oncology. It improves functional capacity, cardiac function, and cardiac biomarkers. Regular assessment and referral to cardio-oncology exercise programs are recommended to mitigate the risk of cardiotoxicity, although challenges exist in implementing such services globally.

Q5: What are the key findings from the EchoRisk study related to cardio-oncology?

A5: The EchoRisk study has provided a multicentre echocardiography dataset with explicit cardiotoxicity labels. It highlights therapy-induced cardiotoxicity as a major non-oncological cause of treatment interruption in breast cancer patients. The study aims to improve early, automated risk stratification using routine cardiac imaging, which remains an open problem in the field.

Q6: How does the FDA's Oncology Center of Excellence contribute to cardio-oncology?

A6: The FDA's Oncology Center of Excellence (OCE) aims to improve patient outcomes by supporting strategies to monitor, prevent, and manage cardiovascular complications from cancer therapies. It promotes scientific research to understand cardiovascular toxicity mechanisms and encourages collaboration across academia, industry, and patient advocacy groups.

Q7: What are the challenges in embedding cardiovascular risk assessment in cancer treatment according to recent studies?

A7: Recent studies indicate that embedding cardiovascular risk assessment into routine management of cancer treatments like BTK inhibitors in chronic lymphocytic leukemia is challenging. There is a need for institutional support in resource allocation, staff recruitment, and the establishment of facilities to integrate these assessments effectively into patient care.

References:

• Oncodaily
• Escardio
• Ascopost
• Jacc
• Fda
• Escardio
• Ic os